Importantly, our findings were of clinical relevance and showed that BMS309403 (a FABP4 inhibitor) could effectively alleviate the development of RA by ameliorating synovitis, angiogenesis, and cartilage degradation in mice. This evidence concerns the gene FABP4 and rheumatoid arthritis.